FO-TI: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Fo-ti (Polygonum multiflorum) is the root of a climbing plant native to east Asia. It's one of the most popular herbs used in traditional Chinese medicine.

Fo-ti might affect levels of various chemicals in the body that are thought to have anti-aging effects. Fo-ti might also increase the number of hair follicles and stimulate hair growth.

People use fo-ti for aging, decline in memory and thinking skills, hair loss, Alzheimer disease, heart disease, and many other conditions, but there is no good scientific evidence to support these uses.

Don't confuse fo-ti with knotweed or hu zhang. These are not the same.

Uses & Effectiveness

We currently have no information for FO-TI overview.

Side Effects

When taken by mouth: Fo-ti is possibly unsafe. Fo-ti has been linked to several cases of liver damage.

When applied to the skin: There isn't enough information available to know if fo-ti is safe or what the side effects might be.

Special Precautions and Warnings

Pregnancy: Fo-ti is possibly unsafe when taken by mouth during pregnancy. Fo-ti contains chemicals that can act like a strong laxative. The chemicals work by stimulating the intestine. Bulk-forming laxatives are a safer choice in pregnancy. There isn't enough reliable information to know if fo-ti is safe to apply to the skin when pregnant. Stay on the safe side and avoid use.

Breast-feeding: Fo-ti is possibly unsafe when taken by mouth while breast-feeding. Chemicals in fo-ti can act like a laxative. These chemicals can pass into breast milk and cause diarrhea in the infant. There isn't enough reliable information to know if fo-ti is safe to apply to the skin when breast-feeding. Stay on the safe side and avoid use.

Children: Fo-ti is possibly unsafe when taken by mouth by children. At least one case of liver damage has been linked with fo-ti use in a 5-year-old child.

Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids: Fo-ti extract might act like estrogen. If you have any condition that might be made worse by exposure to estrogen, don't use fo-ti.

Liver disease: Fo-ti has been linked to multiple cases of liver damage. Fo-ti might make existing liver disease worse and may also increase the risk of bleeding in patients with liver disease.

Surgery: Fo-ti might affect blood sugar levels and slow blood clotting. This might interfere with blood sugar control and blood clotting during and after surgery. Stop using fo-ti at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Digoxin (Lanoxin) interacts with FO-TI
Fo-ti is a type of laxative called a stimulant laxative. Stimulant laxatives can decrease potassium levels in the body. Low potassium levels can increase the risk of side effects from digoxin.
Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications for diabetes (Antidiabetes drugs) interacts with FO-TI
Fo-ti might lower blood sugar levels. Taking fo-ti along with diabetes medications might cause blood sugar to drop too low. Monitor your blood sugar closely.
Medications that can harm the liver (Hepatotoxic drugs) interacts with FO-TI
Fo-ti might harm the liver. Some medications can also harm the liver. Taking fo-ti along with a medication that can harm the liver might increase the risk of liver damage.
Stimulant laxatives interacts with FO-TI
Fo-ti is a type of laxative called a stimulant laxative. Stimulant laxatives can cause diarrhea and decrease potassium levels. Taking fo-ti with other stimulant laxatives might cause more diarrhea and very low potassium levels.
Warfarin (Coumadin) interacts with FO-TI
Fo-ti can work as a laxative. In some people, fo-ti can cause diarrhea. Diarrhea can increase the effects of warfarin and increase the risk of bleeding. Fo-ti can cause damage to the liver, which also can increase the effects of warfarin and increase the risk of bleeding. If you take warfarin, avoid fo-ti.
Water pills (Diuretic drugs) interacts with FO-TI
Fo-ti is a laxative. Some laxatives can cause diarrhea and decrease potassium levels. "Water pills" can also decrease potassium levels. Taking fo-ti along with "water pills" might make potassium levels drop too low.
Birth control pills (Contraceptive drugs) interacts with FO-TI
Some birth control pills contain estrogen. Fo-ti might have some of the same effects as estrogen. Taking fo-ti along with birth control pills might decrease the effects of birth control pills. If you take birth control pills along with fo-ti, use an additional form of birth control such as a condom.
Estrogens interacts with FO-TI
Large amounts of fo-ti might have some of the same effects as estrogen. Taking fo-ti along with estrogen pills might decrease the effects of estrogen pills.
Medications changed by the liver (Cytochrome P450 2B6 (CYP2B6) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) interacts with FO-TI
Some medications are changed and broken down by the liver. Fo-ti might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Sulindac (Clinoril) interacts with FO-TI
Fo-ti might change the effects and side effects of sulindac. Depending on the plant part used, some extracts might increase effects while others might decrease the effects.

Dosing

Some fo-ti products use the raw root of the plant (sometimes called white fo-ti). Other products use a processed form of the root (sometimes called red fo-ti). These products have different effects. There isn't enough reliable information to know what an appropriate dose of fo-ti might be. It might also be unsafe. Speak with a healthcare provider before use.

View References

REFERENCES:

Koh, J. M., Lee, Y. S., Byun, C. H., Chang, E. J., Kim, H., Kim, Y. H., Kim, H. H., and Kim, G. S. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. J Endocrinol. 2005;185(3):401-413. View abstract.

Konrad T, Vicini P, Kusterer K, et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with Type 2 diabetes. Diabetes Care 1999;22:280-7. View abstract.

Korkina L. G., Afanas'ef I. B., Diplock A. T. Antioxidant therapy in children affected by irradiation from the Chernobyl nuclear accident. Biochem Soc Trans 1993;21 ( Pt 3)(3):314S. View abstract.

Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev. 2017 May;18(4):594-601. View abstract.

Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology 1999;13:1003-8. View abstract.

Lai S, Petramala L, Muscaritoli M, et al. a-lipoic acid in patients with autosomal dominant polycystic kidney disease. Nutrition. 2020;71:110594. View abstract.

Laky B, Bruckmann C, Blumenschein J, Durstberger G, Haririan H. Effect of a multi-nutrient supplement as an adjunct to nonsurgical treatment of periodontitis: A randomized placebo-controlled clinical trial. J Periodontol 2024; 95(2): 101-113. View abstract.

Latini E, Bonasia G, Petroselli L, et al. Alpha-Lipoic Acid, Palmitoylethanolamide, Myrrh, and Oxygen-Ozone Therapy Improve Pharmacological Therapy in Acute Painful Lumbosacral Radiculopathy due to Herniated Disc. Pain Physician 2023;26(4):E363-E373. View abstract.

Lee SJ, Jeong SJ, Lee YC, et al. Effects of high-dose alpha-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J. 2017 Aug;41(4):275-83. View abstract.

Lee, S. H., Kim, M. J., Kim, B. J., Kim, S. R., Chun, S., Ryu, J. S., Kim, G. S., Lee, M. C., Koh, J. M., and Chung, S. J. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Mov Disord. 2-15-2010;25(3):332-340. View abstract.

Leong J. Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ 2010;19(10):584-591. View abstract.

Letizia Mauro G, Cataldo P, Barbera G, Sanfilippo A. a-Lipoic acid and superoxide dismutase in the management of chronic neck pain: a prospective randomized study. Drugs R D 2014;14(1):1-7. View abstract.

Li N, Yan W, Hu X, et al. Effects of oral a-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2017;86(5):680-7. View abstract.

Libonati GA, Leone A, Martellucci S, et al. Prevention of Recurrent Benign Paroxysmal Positional Vertigo: The Role of Combined Supplementation with Vitamin D and Antioxidants. Audiol Res. 2022 Aug 22;12(4):445-456. View abstract.

Liu F., Zhang Y., Yang M., Liu B., Shen Y. D., Jia W. P., Xiang K. S. [Curative effect of alpha-lipoic acid on peripheral neuropathy in type 2 diabetes: a clinical study]. Zhonghua Yi Xue Za Zhi 2007;87(38):2706-2709. View abstract.

Lopez-D'alessandro E., Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011;16(5):e635-e640. View abstract.

López-Jornet P., Camacho-Alonso F., and Leon-Espinosa, S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil 2009;36(1):52-57. View abstract.

Lott I. T., Doran E., Nguyen V. Q., Tournay A., Head E., Gillen D. L. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 2011;155A(8):1939-1948. View abstract.

Maesaka H, Komiya K, Misugi K, Tada K. Hyperalaninemia hyperpyruvicemia and lactic acidosis due to pyruvate carboxylase deficiency of the liver; treatment with thiamine and lipoic acid. Eur J Pediatr 1976;122:159-68. View abstract.

Magis D., Ambrosini A., Sandor P., Jacquy J., Laloux P., Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007;47(1):52-57. View abstract.

Mahmoudinezhad M, Farhangi MA. Alpha lipoic acid supplementation affects serum lipids in a dose and duration-dependent manner in different health status. Int J Vitam Nutr Res 2021. View abstract.

Marino R., Torretta S., Capaccio P., Pignataro L., Spadari F. Different therapeutic strategies for burning mouth syndrome: preliminary data. J Oral Pathol Med 2010;39(8):611-616. View abstract.

Marshall AW, Graul RS, Morgan MY, Sherlock S. Treatment of alcohol-related liver disease with thioctic acid: a six-month, randomized, double-blind trial. Gut 1982;23:1088-93. View abstract.

Matalon R, Stumpf DA, Michals K, et al. Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. J Pediatr 1984;104:65-9. View abstract.

Mazloom Z., Ansar H. The Effect of Alpha-Lipoic Acid on Blood Pressure in Type 2 Diabetics. Iranian Journal of Endocrinology and Metabolism 2009;11(3):245-250.

Memeo A., Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. Clin Drug Investig 2008;28(8):495-500. View abstract.

Merin JP, Matsuyama M, Kira T, et al. Alpha-lipoic acid blocks HIV-1 LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett 1996;394:9-13. View abstract.

Mishra A, Reeta KH, Sarangi SC, Maiti R, Sood M. Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial. Psychopharmacology (Berl) 2022;239(11):3525-35. View abstract.

Moffa S, Improta I, Rocchetti S, Mezza T, Giaccari A. Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: Two case reports. Nutrition. 2019;57:1-4. View abstract.

Mohammadshahi M, Zakizadeh E, Ahmadi-Angali K, Ravanbakhsh M, Helli B. The synergic effects of alpha-lipoic acid supplementation and electrical isotonic contraction on anthropometric measurements and the serum levels of VEGF, NO, sirtuin-1, and PGC1-α in obese people undergoing a weight loss diet. Arch Physiol Biochem. 2020:1-7. View abstract.

Moretti R, Angeletti C, Minora S. Multiple organ failure and shock following acute alpha lipoic acid (ALA) intoxication. Clin Toxicol (Phila). 2019;57(8):749-751. View abstract.

Murray GL, Colombo J. (r)Alpha lipoic acid is a safe, effective pharmacologic therapy of chronic orthostatic hypotension associated with low sympathetic tone. Int J Angiol. 2019;28(3):188-193. View abstract.

Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabet Care 1995;18:1160-7. View abstract.

Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2017 Jun 8 pii:S0261-5614(17)30212-1.View abstract.

Orellana-Donoso M, López-Chaparro M, Barahona-Vásquez M, et al. Effectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type I and type II diabetes mellitus: A systematic review and meta-analysis. Medicine (Baltimore) 2023;102(44):e35368. View abstract.

Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-78. View abstract.

Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50. View abstract.

Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann N Y Acad Sci 1994;738:257-64. View abstract.

Parente E, Colannino G, Picconi O, Monastra G. Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study. Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4219-27. View abstract.

Passiatore M, Perna A, De-Vitis R, Taccardo G. The use of alfa-lipoic acid-R (ALA-R) in patients with mild-moderate carpal tunnel syndrome: A randomised controlled open label prospective study. Malays Orthop J. 2020;14(1):1-6. View abstract.

Pingali U, Sravanasandya P, Mekala P, Yareeda S, Sireesha K, Khan I. A randomized, double-blind, placebo-controlled study to evaluate the effect of alpha-lipoic acid on inhibition of ADP-and collagen-induced platelet aggregation ex vivo in diabetic neuropathy patients on gabapentin or pregabalin. J Postgrad Med 2024;70(4):191-197. View abstract.

Podymova S. D., Davletshina I. V. [Efficacy of using alpha-lipoic acid (berlition) in patients with nonalcoholic steatohepatitis]. Eksp Klin Gastroenterol 2008;(5):77-84. View abstract.

Polat S, Kiliçaslan Ö, Sönmez FT. Alpha-lipoic acid intoxication in an adolescent girl: Case report and review of the literature. Turk Pediatri Ars. 2020;55(3):328-330. View abstract.

Porasuphatana S., Suddee S., Nartnampong A., Konsil J., Harnwong B., Santaweesuk A. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. Asia Pac J Clin Nutr 2012;21(1):12-21. View abstract.

Porcaro G, Laganà AS, Neri I, Aragona C. The Association of High-Molecular-Weight Hyaluronic Acid (HMWHA), Alpha Lipoic Acid (ALA), Magnesium, Vitamin B6, and Vitamin D Improves Subchorionic Hematoma Resorption in Women with Threatened Miscarriage: A Pilot Clinical Study. J Clin Med 2024;13(3):706. View abstract.

Prado MB Jr, Adiao KJB. Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis. Can J Diabetes 2024;48(4):233-243. View abstract.

Prasad KN. Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy. J Nutr 2004;134:3182S-3S. View abstract.

Avula, B., Joshi, V. C., Wang, Y. H., and Khan, I. A. Simultaneous identification and quantification of anthraquinones, polydatin, and resveratrol in Polygonum multiflorum, various Polygonum species, and dietary supplements by liquid chromatography and microscopic study of Polygonum species. J AOAC Int 2007;90(6):1532-1538. View abstract.

Bae, S. H., Kim, D. H., Bae, Y. S., Lee, K. J., Kim, D. W., Yoon, J. B., Hong, J. H., and Kim, S. H. [Toxic hepatitis associated with Polygoni multiflori]. Korean J.Hepatol. 2010;16(2):182-186. View abstract.

Chen, H. and Weng, L. [Comparison on efficacy in treating liver fibrosis of chronic hepatitis B between Astragalus Polygonum anti-fibrosis decoction and jinshuibao capsule]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2000;20(4):255-257. View abstract.

Chen, J. [An experimental study on the anti-senility effects of shou xing bu zhi]. Zhong.Xi.Yi.Jie.He.Za Zhi. 1989;9(4):226-7, 198. View abstract.

Chen, L. W., Wang, Y. Q., Wei, L. C., Shi, M., and Chan, Y. S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS.Neurol.Disord.Drug Targets. 2007;6(4):273-281. View abstract.

Chen, L., Huang, J., and Xue, L. [Effect of compound Polygonum multiflorum extract on Alzheimer's disease]. Zhong.Nan.Da.Xue.Xue.Bao.Yi.Xue.Ban. 2010;35(6):612-615. View abstract.

Choi, S. G., Kim, J., Sung, N. D., Son, K. H., Cheon, H. G., Kim, K. R., and Kwon, B. M. Anthraquinones, Cdc25B phosphatase inhibitors, isolated from the roots of Polygonum multiflorum Thunb. Nat.Prod.Res 5-20-2007;21(6):487-493. View abstract.

Foster, S. and Tyler, V. E. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. Binghamton, NY: Haworth Herbal Press;1993.

Furukawa, M., Kasajima, S., Nakamura, Y., Shouzushima, M., Nagatani, N., Takinishi, A., Taguchi, A., Fujita, M., Niimi, A., Misaka, R., and Nagahara, H. Toxic hepatitis induced by show-wu-pian, a Chinese herbal preparation. Intern.Med. 2010;49(15):1537-1540. View abstract.

Grech, J. N., Li, Q., Roufogalis, B. D., and Duck, C. C. Novel Ca(2+)-ATPase inhibitors from the dried root tubers of Polygonum Multiflorum. J.Nat.Prod. 1994;57(12):1682-1687. View abstract.

Horikawa, K., Mohri, T., Tanaka, Y., and Tokiwa, H. Moderate inhibition of mutagenicity and carcinogenicity of benzo[a]pyrene, 1,6-dinitropyrene and 3,9-dinitrofluoranthene by Chinese medicinal herbs. Mutagenesis 1994;9(6):523-526. View abstract.

Huang, H. C., Chu, S. H., and Chao, P. D. Vasorelaxants from Chinese herbs, emodin and scoparone, possess immunosuppressive properties. Eur.J.Pharmacol. 6-6-1991;198(2-3):211-213. View abstract.

Huang, W. Y., Cai, Y. Z., Xing, J., Corke, H., and Sun, M. Comparative analysis of bioactivities of four Polygonum species. Planta Med 2008;74(1):43-49. View abstract.

Kang, S. C., Lee, C. M., Choi, H., Lee, J. H., Oh, J. S., Kwak, J. H., and Zee, O. P. Evaluation of oriental medicinal herbs for estrogenic and antiproliferative activities. Phytother Res 2006;20(11):1017-1019. View abstract.

Ling, S., Nheu, L., Dai, A., Guo, Z., and Komesaroff, P. Effects of four medicinal herbs on human vascular endothelial cells in culture. Int J Cardiol. 8-29-2008;128(3):350-358. View abstract.

Liu, C., Zhang, Q., and Lin, J. [Effect of the root of Polygonum multiflorum Thunb. and its processed products on fat accumulation in the liver of mice]. Zhongguo Zhong.Yao Za Zhi. 1992;17(10):595-6, 639. View abstract.

Liu, Q. L., Xiao, J. H., Ma, R., Ban, Y., and Wang, J. L. Effect of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. J Asian Nat.Prod.Res 2007;9(6-8):689-697. View abstract.

McGuffin, M., Hobbs, C., Upton, R., and Goldberg, A. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC;1997.

Ryu, G., Ju, J. H., Park, Y. J., Ryu, S. Y., Choi, B. W., and Lee, B. H. The radical scavenging effects of stilbene glucosides from Polygonum multiflorum. Arch.Pharm.Res. 2002;25(5):636-639. View abstract.

Wang, X., Zhao, L., Han, T., Chen, S., and Wang, J. Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. Eur.J Pharmacol. 1-14-2008;578(2-3):339-348. View abstract.

Weiying, L., Yuanjiang, D., and Baolian, L. Treatment of the localized neurodermatitis by plum-blossom needle tapping and with the modified yangxue dingfeng tang--a clinical observation of 47 cases. J.Tradit.Chin Med. 2006;26(3):181-183. View abstract.

Xu, M. L., Zheng, M. S., Lee, Y. K., Moon, D. C., Lee, C. S., Woo, M. H., Jeong, B. S., Lee, E. S., Jahng, Y., Chang, H. W., Lee, S. H., and Son, J. K. A new stilbene glucoside from the roots of Polygonum multiflorum Thunb. Arch Pharm Res 2006;29(11):946-951. View abstract.

Yan, Y., Su, X., Liang, Y., Zhang, J., Shi, C., Lu, Y., Gu, L., and Fu, L. Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol Cancer Ther 2008;7(6):1688-1697. View abstract.

Yang, P. Y., Almofti, M. R., Lu, L., Kang, H., Zhang, J., Li, T. J., Rui, Y. C., Sun, L. N., and Chen, W. S. Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum. J Pharmacol.Sci 2005;99(3):294-300. View abstract.

Yao, S., Li, Y., and Kong, L. Preparative isolation and purification of chemical constituents from the root of Polygonum multiflorum by high-speed counter-current chromatography. J Chromatogr.A 5-19-2006;1115(1-2):64-71. View abstract.

Yuen, M. F., Tam, S., Fung, J., Wong, D. K., Wong, B. C., and Lai, C. L. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment.Pharmacol.Ther 10-15-2006;24(8):1179-1186. View abstract.

Zhang, L., Yang, X., Sun, Z., and Qu, Y. [Retrospective study of adverse events of Polygonum multiflorum and risk control]. Zhongguo Zhong.Yao Za Zhi. 2009;34(13):1724-1729. View abstract.

Zhang, Z. G., Lu, T. S., and Yao, Q. Q. [Effect of preparation on the major chemical constituents of Polygonum multiflorum]. Zhong.Yao Cai. 2006;29(10):1017-1019. View abstract.

Zhong, J., Tian, J. Z., Zhu, A. H., and Yang, C. Z. [Clinical study on a randomized, double-blind control of Shenwu gelatin capsule in treatment of mild cognitive impairment]. Zhongguo Zhong.Yao Za Zhi. 2007;32(17):1800-1803. View abstract.

Zuo, G. Y., Wang, G. C., Zhao, Y. B., Xu, G. L., Hao, X. Y., Han, J., and Zhao, Q. Screening of Chinese medicinal plants for inhibition against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). J Ethnopharmacol. 11-20-2008;120(2):287-290. View abstract.

Bounda GA, Feng YU. Review of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds. Pharmacognosy Res 2015;7(3):225-236. View abstract.

But PP, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Hum Toxicol 1996;38:280-2. View abstract.

Cardenas A, Restrepo JC, Sierra F, Correa G. Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiflorum. J Clin Gastroenterol 2006;40:629-32. View abstract.

Choi RY, Lee MK. Polygonum multiflorum Thunb. hot water extract reverses high-fat diet-induced lipid metabolism of white and brown adipose tissues in obese mice. Plants (Basel) 2021;10(8):1509. View abstract.

Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed. Washington, DC: American Pharmaceutical Association, 1996.

Dong H, Slain D, Cheng J, Ma W, Liang W. Eighteen cases of liver injury following ingestion of Polygonum multiflorum. Complement Ther Med 2014;22(1):70-4. View abstract.

Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus based multiherb formula for dyslipidemia: a randomized, double blind, placebo controlled clinical trial. Evid Based Complement Alternat Med 2014;2014:365742. View abstract.

Hwang YH, Kang KY, Kim JJ, et al. Effects of hot water extracts from Polygonum multiflorum on ovariectomy induced osteopenia in mice. Evid Based Complement Alternat Med 2016;2016:8970585. View abstract.

Jung KA, Min HJ, Yoo SS, et al. Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb. Gut Liver 2011;5(4):493-9. View abstract.

Laird AR, Ramchandani N, deGoma EM, et al. Acute hepatitis associated with the use of an herbal supplement (Polygonum multiflorum) mimicking iron-overload syndrome. J Clin Gastroenterol 2008;42:861-2. View abstract.

Lei X, Chen J, Ren J, et al. Liver damage associated with Polygonum multiflorum Thunb.: a systematic review of case reports and case series. Evid Based Complement Alternat Med 2015;2015:459749. View abstract.

Li RW, David Lin G, Myers SP, Leach DN. Anti-inflammatory activity of Chinese medicinal vine plants. J Ethnopharmacol 2003;85:61-7. View abstract.

Liu Y, Zhou M, Wang R, et al. Alleviation of Glucocorticoid-Induced Osteoporosis in Rats by Ethanolic Reynoutria multiflora (Thunb.) Moldenke Extract. J Med Food 2024;27(4):287-300. View abstract.

Ma KF, Zhang XG, Jia HY. CYP1A2 polymorphism in Chinese patients with acute liver injury induced by Polygonum multiflorum. Genet Mol Res 2014;13(3):5637-43. View abstract.

Ma N, Zhang Y, Sun L, Zhao Y, Ding Y, Zhang T. Comparative studies on multi-component pharmacokinetics of Polygonum multiflorum Thunb extract after oral administration in different rat models. Front Pharmacol 2021;12:655332. View abstract.

Mazzanti G, Battinelli L, Daniele C, et al. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum. Ann Intern Med 2004;140:E589-90. View abstract.

Oerter Klein KO, Janfaza M, Wong JA, Chang RJ. Estrogen bioactivity in Fo-Ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J Clin Endocrinol Metab 2003;88:4077-9.. View abstract.

Panis B, Wong DR, Hooymans PM, De Smet PA, Rosias PP. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. J Pediatr Gastroenterol Nutr 2005;41:256-8. View abstract.

Park GJ, Mann SP, Ngu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol 2001;16:115-7. View abstract.

Park HJ, Zhang N, Park DK. Topical application of Polygonum multiflorum extract induces hair growth of resting hair follicles through upregulating Shh and ??-catenin expression in C57BL/6 mice. J Ethnopharmacol 2011;135(2):369-75. View abstract.

Shao YL, Ma CM, Wu JM, Guo FC, Zhang SC. Concurrent severe hepatotoxicity and agranulocytosis induced by Polygonum multiflorum: A case report. World J Clin Cases 2022;10(27):9921-9928. View abstract.

Sun YN, Cui L, Li W, et al. Promotion effect of constituents from the root of Polygonum multiflorum on hair growth. Bioorg Med Chem Lett 2013;23(17):4801-5. View abstract.

UK Medicines and Healthcare Products Regulatory Agency. Polygonum multiflorum and liver reactions. April 2006. Available at: www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&useSecondary=true&ssDocName= CON2023590&ssTargetNodeId= 833 (Accessed 10 May 2006).

Um MY, Choi WH, Aan JY, Kim SR, Ha TY. Protective effect of Polygonum multiflorum Thunb on amyloid beta-peptide 25-35 induced cognitive deficits in mice. J Ethnopharmacol 2006;104:144-8. View abstract.

Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.

Xing Y, Yu Q, Zhou L, et al. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays. Phytomedicine 2023;112:154710. View abstract.

Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.

Yu J, Xie J, Mao XJ, et al. Comparison of laxative and antioxidant activities of raw, processed and fermented Polygoni multiflori radix. Chin J Nat Med 2012;10(1):63-7. View abstract.

Zhang CZ, Wang SX, Zhang Y, et al. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol 2005;98:295-300. View abstract.

Zhang L, Huang L, Chen L, Hao D, Chen J. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease. Toxicol Lett 2013;222:155-63. View abstract.

Zhang Y, Ding T, Diao T, Deng M, Chen S. Effects of Polygonum multiflorum on the activity of cytochrome P450 isoforms in rats. Pharmazie 2015;70(1):47-54. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

FO-TI - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Side Effects

Special Precautions and Warnings

Interactions

Moderate Interaction

Digoxin (Lanoxin) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with FO-TI

Medications for diabetes (Antidiabetes drugs) interacts with FO-TI

Medications that can harm the liver (Hepatotoxic drugs) interacts with FO-TI

Stimulant laxatives interacts with FO-TI

Warfarin (Coumadin) interacts with FO-TI

Water pills (Diuretic drugs) interacts with FO-TI

Birth control pills (Contraceptive drugs) interacts with FO-TI

Estrogens interacts with FO-TI

Medications changed by the liver (Cytochrome P450 2B6 (CYP2B6) substrates) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with FO-TI

Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) interacts with FO-TI

Sulindac (Clinoril) interacts with FO-TI

Dosing